QuadMedicine Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	10,698	9,304	1,012
Revenue Growth (YoY)	14.99%	819.58%	-
Gross Profit	10,698	9,304	1,012
Selling, General & Admin	1,826	1,337	1,413
Research & Development	15,014	12,269	9,006
Other Operating Expenses	73.63	2.75	2.91
Operating Expenses	17,082	13,753	10,531
Operating Income	-6,384	-4,449	-9,519
Interest Expense	-349.97	-370.45	-114.15
Interest & Investment Income	90.26	23.9	107.11
Currency Exchange Gain (Loss)	-42.06	129.9	20.89
Other Non Operating Income (Expenses)	-228.99	-302.32	-249.92
EBT Excluding Unusual Items	-6,915	-4,968	-9,755
Gain (Loss) on Sale of Assets	-16.34	-	-3.14
Pretax Income	-6,931	-4,968	-9,759
Net Income	-6,931	-4,968	-9,759
Net Income to Common	-6,931	-4,968	-9,759
Shares Outstanding (Basic)	10	9	9
Shares Outstanding (Diluted)	10	9	9
Shares Change (YoY)	10.14%	0.93%	-
EPS (Basic)	-722.00	-570.00	-1129.97
EPS (Diluted)	-722.00	-570.00	-1130.00
Free Cash Flow	-6,738	-2,214	-10,056
Free Cash Flow Per Share	-701.89	-254.01	-1164.44
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-59.67%	-47.82%	-940.90%
Profit Margin	-64.79%	-53.40%	-964.54%
Free Cash Flow Margin	-62.98%	-23.80%	-993.97%
EBITDA	-3,088	-1,297	-7,448
EBITDA Margin	-28.87%	-13.94%	-
D&A For EBITDA	3,296	3,153	2,071
EBIT	-6,384	-4,449	-9,519
EBIT Margin	-59.67%	-47.82%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.